Addex Therapeutics (ADXN)
(Delayed Data from NSDQ)
$8.00 USD
-0.12 (-1.48%)
Updated Jul 24, 2024 09:58 AM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Price, Consensus and EPS Surprise
ADXN 8.00 -0.12(-1.48%)
Will ADXN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ADXN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ADXN
Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q3 Loss, Tops Revenue Estimates
ADXN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q2 Loss, Misses Revenue Estimates
TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates
Other News for ADXN
After Disappointing Data, Johnson & Johnson Halts Developing Epilepsy Drug Candidate
Addex Therapeutics partner discontinues development of ADX71149
Addex?s Partner Discontinues ADX71149 development in Epilepsy
J&J ends work on Addex epilepsy drug candidate ADX71149: report
Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)